Cosibelimab-A must-read guide for patients on the market for UNLOXCYT

Cosibelimab (UNLOXCYT) is a programmed death ligand -1 (PD-L1) blocking antibody that activates the immune system to attack cancer cells by blocking the binding of PD-L1 and PD-1. The drug is indicated for the treatment of adult patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced cutaneous squamous cell carcinoma (laCSCC), particularly those who are not candidates for curative surgery or radical radiotherapy. In December 2024, cosibelimab was officially approved by the U.S. Food and Drug Administration (FDA) and became an important option for the treatment of cutaneous squamous cell carcinoma.

The recommended dose of cosibelimab is 1200 mg administered by intravenous infusion every 3 weeks over approximately 60 minutes. Treatment should be continued until disease progression or unacceptable toxicity occurs. Before patients receive treatment, their condition and physical condition need to be evaluated by a professional doctor to ensure the suitability of the drug.

Based on clinical trial data, the most common adverse reactions (incidence≥10%) of cosibelimab include fatigue, musculoskeletal pain, rash, diarrhea, hypothyroidism, constipation, nausea, headache, pruritus, edema, local infection and urinary tract infection. Patients should pay close attention to their own conditions during treatment. If they experience serious discomfort, they need to communicate with their doctor in time.

Because cosibelimab works by activating the immune system, it may cause immune-related adverse reactions, such as pneumonia, hepatitis, colitis, etc. Patients need to undergo relevant examinations regularly to detect and deal with potential problems in a timely manner. During treatment, patients may be at increased risk of infection due to activation of the immune system. It is recommended to avoid contact with sources of infection and to observe personal hygiene. The safety of cosibelimab in pregnant women, lactating women and children has not yet been determined and needs to be carefully evaluated.

As of now, cosibelimab has not yet been launched in China, and since it has just been launched in the United States, there is no clear price information in public information. Referring to the price of PD-L1 antibody drugs of the same type, cosibelimab may be at a higher level. Patients can consult relevant medical institutions through formal channels to learn about the access and cost of drugs.

cosibelimab-UNLOXCYTIt provides a new treatment option for patients with cutaneous squamous cell carcinoma, but its use must be under the guidance of a professional doctor. With further promotion and research of the drug, it is expected to bring hope to more patients in the future.

https://ir.checkpointtx.com/news-events/press-releases/detail/127/checkpoint-therapeutics-announces-fda-approval-of